PETS · Petmed Express Inc · Insider Trading

Performance Share Units ("PSUs") granted pursuant to the 2024 Inducement Incentive Plan. Each PSU represents a contingent right to receive one share of the Company's Common Stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Inducement Incentive Plan that will vest as to one-third of the granted shares on each of the first three anniversaries of the grant date, subject to continued employment and subject to accelerated vesting upon death, disability, a change of control, or certain terminations of employment.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan which will vest in its entirety on September 17, 2027, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that will vest as to all shares on the first anniversary of the grant date, subject to continued employment and subject to accelerated vesting upon death, disability, a change of control, or certain terminations of employment.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on August 11, 2027, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on August 11, 2027, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on August 11, 2027, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to 50% of granted shares on June 26, 2027, and 50% on June 26, 2028, subject to continued employment through each such vesting date.

Performance Share Units ("PSUs") granted pursuant to the 2024 Omnibus Incentive Plan. Each PSU represents a contingent right to receive one share of the Company's Common Stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a two-year performance period beginning on April 1, 2026 ending on March 31, 2028.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $1.72 to $1.75, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,875,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 725,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

This Form 4 is being filed to reflect the automatic forfeiture, in accordance with the applicable award agreement, of a portion of the restricted shares granted on October 30, 2025 to the reporting person due to the termination of director service by the reporting person as of January 21, 2026.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to 50% of granted shares on October 30, 2026, and 50% on October 30, 2027, subject to continued employment through each such vesting date.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors.

Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan , of which 1,020 shares will vest on October 19, 2026 and 33,846 shares will vest on October 30, 2026, subject to continued service on the Board of Directors.

Restricted stock award granted pursuant to the PetMed Express, Inc. (the "Company") 2024 Omnibus Incentive Plan (the "2024 Omnibus Plan"). The award will vest in its entirety on the 6-month anniversary of the grant date so long as Mr. Krulik remains on such date employed by the Company or otherwise in the service of the Company (as a director, consultant, or otherwise) and the award will vest in full in the event that the Company terminates the service by Mr. Krulik with the Company prior to the full vesting of the award unless such termination is for Cause (within the meaning 2024 Omnibus Plan).

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $3.4935 to $3.4999, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,875,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 700,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.97, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,875,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 675,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $3.83 to $3.89, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,875,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 650,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

Shares sold solely to cover tax withholding obligations due upon vesting of restricted stock units on April 30, 2025.

Includes 473,834 restricted stock units ("RSUs") that are subject to vesting in accordance with the applicable RSU award agreements.

Shares sold solely to cover tax withholding obligations due upon vesting of restricted stock units on April 30, 2025.

Consists of restricted stock units ("RSUs") granted pursuant to the PetMed Express, Inc. (the "Company") Non-Employee Director Equity Compensation Program, which vest on April 9, 2026, subject to continued service on the Board of Directors of the Company through the vesting period. Each RSU represents a right to receive one share of the Company's Common Stock upon vesting.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.08 to $4.09, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,875,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 625,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.09 to $4.13, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,775,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 625,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.29 to $4.36, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,675,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 625,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.81 to $4.83, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,625,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 625,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.67, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,625,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 600,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.9283 to $4.9648, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,625,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 575,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

Consists of restricted stock units ("RSUs") granted pursuant to the PetMed Express, Inc. (the "Company") 2024 Omnibus Incentive Plan. One-third of the RSUs vest on each of the first, second and third anniversaries of January 15, 2025, subject to continued employment with the Company through the restricted periods (except as provided in the RSU agreement). Each RSU represents a right to receive one share of the Company's Common Stock upon vesting.

Performance Share Units ("PSUs") granted pursuant to the Plan. Each PSU represents a contingent right to receive one share of the Company's Common Stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on December 31, 2027.

Consists of restricted stock units ("RSUs") granted pursuant to the PetMed Express, Inc. (the "Company") 2024 Omnibus Incentive Plan. One-third of the RSUs vest on each of the first, second and third anniversaries of January 15, 2025, subject to continued employment with the Company through the restricted periods (except as provided in the RSU agreement). Each RSU represents a right to receive one share of the Company's Common Stock upon vesting.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $4.9538 to $4.9963, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,625,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 550,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $5.6213 to $5.6926, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,600,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 550,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

The sales price reported is the weighted average sale price for the number of shares of Common Stock purchased. These shares were purchased in multiple transactions at prices ranging from $5.48 to $5.62, inclusive. Full information regarding the number of shares purchased at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer.

Includes (i) 1,590,000 shares of Common Stock held by Nina Capital Holdings, and (ii) 528,000 shares of Common Stock held jointly by Moises Tache Galante and his spouse, Stephannie Matz Zyman.

Reflects the weighted average purchase price. The range of prices for such transaction is $5.3998 to $5.4300. Open market purchase transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within the price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Reflects the weighted average purchase price. The range of prices for such transaction is $5.395 to $5.460. Open market purchase transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within the price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares are held in a trust for the benefit of the family members of the reporting person. The spouse of the reporting person is trustee of the trust, but the reporting person is not a beneficiary of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Reflects the weighted average purchase price. The range of prices for such transaction is $5.4050 to $5.4086. Open market purchase transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within the price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares are held in a trust for the benefit of the family members of the reporting person. The spouse of the reporting person is trustee of the trust, but the reporting person is not a beneficiary of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These shares are held in a trust for the benefit of the family members of the reporting person. The spouse of the reporting person is trustee of the trust, but the reporting person is not a beneficiary of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These shares are held in a trust for the benefit of the family members of the reporting person. The spouse of the reporting person is trustee of the trust, but the reporting person is not a beneficiary of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.